Keytruda costs roughly $12,000 per infusion at its list price, with most patients receiving treatment every three to six weeks for up to two years. That puts the annual cost somewhere around $175,000 to $200,000 depending on the dosing schedule. The price reflects a combination of expensive manufacturing, massive research investment, limited competition, and the fact that the U.S. allows drugmakers to set their own prices in ways other countries don’t.
What a Single Dose Actually Costs
A standard 200 mg dose of Keytruda carries a list price of roughly $12,000. Since most treatment plans call for infusions every three or six weeks, and courses can run up to two years, total costs can climb well past $300,000 over the full treatment period. These are list prices, meaning the sticker price before insurance negotiations, rebates, or discounts. What hospitals and insurers actually pay is lower, but the list price is what uninsured patients face and what drives cost-sharing for many insured ones.
Biologic Drugs Are Expensive to Make
Keytruda isn’t a pill made from chemical ingredients. It’s a monoclonal antibody, a large, complex protein grown inside living cells. That distinction matters enormously for cost.
Manufacturing starts with Chinese Hamster Ovary (CHO) cells, which are cultured in large bioreactors under tightly controlled conditions. The cell culture medium alone can cost on the order of $1 million per batch. Once the cells produce the antibody, it has to be purified through multiple rounds of specialized filtration and chromatography. The materials for one of these purification steps, called Protein A chromatography, can run into the millions of dollars for a single large batch. Virus filtration membranes are single-use and expensive. Even the buffer solutions used throughout the process add significant cost.
The facilities themselves are capital-intensive. Many biopharmaceutical plants were built with stainless steel equipment designed to produce a single product, requiring enormous upfront investment and long lead times. These plants typically operate at about 70% of their fixed maximum capacity. Compare this to a traditional pill like ibuprofen, which is synthesized from simple chemical reactions in far less specialized equipment, and it’s clear why biologics start at a fundamentally higher cost floor.
Research Costs Spanning Decades
Keytruda didn’t emerge from a single study. The drug has been tested across dozens of cancer types and in hundreds of clinical trials, each of which costs tens to hundreds of millions of dollars to run. Merck has pursued approvals in lung cancer, melanoma, bladder cancer, head and neck cancers, kidney cancer, gastric cancer, and many others. Every new indication requires its own set of trials, regulatory submissions, and sometimes years of follow-up data.
The broader economics of drug development also play a role. Pharmaceutical companies price successful drugs to recoup not just that drug’s development costs but also the cost of every failed candidate that never made it to market. Industry estimates for bringing a single drug from discovery to approval range from $1 billion to over $2 billion, depending on the methodology. Merck folds those R&D economics into Keytruda’s price, and with Keytruda generating the vast majority of the company’s revenue, there’s strong incentive to maximize returns while patent protection lasts.
Patent Protection Limits Competition
Key patents on Keytruda begin to expire in 2028, and until then, no generic or biosimilar version can legally enter the U.S. market. This monopoly period is the window when drugmakers earn back their investment, and it’s also the period when prices are highest because there’s no competitive pressure to lower them.
Once patents expire, biosimilar manufacturers can develop their own versions of the drug. Biosimilars for other cancer antibodies have reduced prices by 20% to 50% in some cases, though the savings tend to be less dramatic than with generic pills. The complexity of manufacturing biologics means biosimilar development itself is expensive, so the market doesn’t see the same steep price drops that happen when, say, a cholesterol pill goes generic. Still, 2028 represents a meaningful inflection point for Keytruda pricing.
The U.S. Pays Far More Than Other Countries
At launch, Keytruda’s price per milligram in the United States was $43.16, compared to $34.52 in the UK, $36.95 in Germany, $29.20 in France, $23.82 in Japan, and $15.83 in China. The U.S. price was nearly three times China’s and roughly 25% higher than the UK’s.
This gap exists because most other developed countries have government agencies that negotiate drug prices directly with manufacturers, often using formal assessments of how much additional health benefit a drug delivers per dollar spent. In France, for instance, one cost-effectiveness analysis found that adding Keytruda to chemotherapy for a type of lung cancer extended quality-adjusted life by about 5.5 months at an additional cost of roughly €53,000 per patient, yielding a cost-per-quality-adjusted-life-year of about €116,600. French regulators use thresholds like these to negotiate prices downward.
The U.S. has historically had no equivalent mechanism. Medicare, the largest single payer for cancer drugs, was prohibited from negotiating prices directly with manufacturers until the Inflation Reduction Act changed that in 2022. Even under the new law, Keytruda has not yet been selected for price negotiation. The first two rounds of selected drugs focused on other high-spend medications. If Keytruda is selected in a future round, any negotiated price wouldn’t take effect until at least 2028, which happens to align with its patent expiration anyway.
How Patients Actually Pay
Most patients with commercial insurance don’t pay the full list price out of pocket, but cost-sharing can still be substantial. Copays or coinsurance for specialty drugs like Keytruda can run thousands of dollars per infusion, depending on the plan. Merck offers a copay assistance program for commercially insured patients, though it doesn’t cover uninsured individuals.
For patients without insurance, Merck runs a patient assistance program that provides the drug for free to U.S. residents who lack prescription drug coverage and can’t afford their medication. Eligibility is based on income, though Merck doesn’t publicly disclose the specific income thresholds. Patients who technically have insurance but face financial hardship may still qualify under a special circumstances provision.
Medicare patients face a different situation. They can’t use manufacturer copay cards, and their out-of-pocket costs depend on whether they’ve hit their plan’s catastrophic coverage threshold. The Inflation Reduction Act’s new $2,000 annual out-of-pocket cap for Medicare Part D helps with some drugs, but Keytruda is administered by infusion in a clinic, which means it falls under Part B, where cost-sharing rules differ.
Why the Price Stays High
Keytruda is the best-selling drug in the world, generating over $25 billion in annual revenue for Merck. That market position creates little incentive to lower the price voluntarily. The drug works across more cancer types than almost any other single therapy, which means demand keeps growing as new indications are approved. Each new approval expands the pool of patients and oncologists who rely on it, reinforcing its market dominance.
Merck is also racing to develop new formulations and combinations that could extend patent protection or maintain market share beyond 2028. The company recently announced plans to create a separate cancer division, a move widely interpreted as preparation for the revenue hit when biosimilar competition eventually arrives. Until that happens, the combination of patent exclusivity, complex manufacturing, no government price negotiation, and broad clinical use keeps Keytruda’s price where it is.